AccurEdit Therapeutics today announced that its innovative in vivo gene editing product, ART001, has obtained Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback